FOLH1 and prostate carcinoma: On the other hand, since Di-peptide has a specific affinity for prostate cancer cells expressing PSMA such as the Lncap cell line, Di-PEG@PTX@ZIF-8 can exhibit the powerful targeting efficiency for all PSMA-positive cell lines and also significantly increase the targeted therapy outcomes for PSMA-positive prostate cancers.